|1.||Kaaks, Rudolf: 50 articles (06/2014 - 03/2002)|
|2.||Colao, Annamaria: 46 articles (06/2015 - 03/2002)|
|3.||Colao, A: 44 articles (11/2013 - 01/2000)|
|4.||Frystyk, Jan: 42 articles (11/2015 - 08/2002)|
|5.||Pollak, Michael N: 41 articles (07/2015 - 07/2002)|
|6.||Pollak, Michael: 40 articles (03/2014 - 07/2002)|
|7.||Clemmons, David R: 38 articles (12/2015 - 03/2002)|
|8.||Flyvbjerg, Allan: 38 articles (11/2015 - 08/2002)|
|9.||Rinaldi, Sabina: 37 articles (06/2014 - 03/2002)|
|10.||Lombardi, G: 36 articles (12/2012 - 01/2000)|
01/01/2011 - "The results of the second postoperative week, 3 months postoperative, and the most recent follow-up OGTT and IGF-1 measurements were used to calculate the positive and negative predictive values of the following endocrinological criteria of acromegaly remission: the common consensus criteria for acromegaly remission, GH suppression to < 1 μg/l during OGTT and IGF-1 within normal limits. "
06/01/2001 - "In conclusion, long-term treatment with OCT-LAR was effective in controlling GH and IGF-I hypersecretion in most patients with acromegaly, when applied either as primary therapy or as adjunctive therapy after surgery. "
03/01/1987 - "The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. "
01/01/2003 - "It has been clearly demonstrated that an extended exposure to GH and IGF-I excess level, even if slight, has a very harmful effect on patients; therefore early diagnosis of acromegaly and appropriate definition of its cure are of fundamental extreme in order to plan a prompt and appropriate therapeutic intervention(s) guaranteed also by the continuous improvement in the therapeutic tools available to treat this systemic disease."
02/01/1991 - "In summary, IGF-I is very reliable in the evaluation of acromegaly activity and only requires a baseline determination being thus very useful in initial screening. "
04/01/2004 - "Overall recurrence risk was significantly greater for tumors that expressed IGF-I-R (p = 0.05) but only approached statistical significance (p = 0.08) when disease-free survival was determined. "
08/01/2012 - "Patients with lower IGF-1 level and with tumors that were less invasive of the cavernous sinus before GKRS were associated with better GH remission rates. "
01/01/2006 - "This allows the speculation that this approach could also prove effective in modulating cancer-induced muscle wasting, while avoiding the potentially hazardous side effects of systemic IGF-1 administration. "
01/01/2005 - "Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation. "
10/01/2014 - "Neither MN nor NDI was correlated with age, GH, IGF-I, initial GH, initial IGF-I, duration of the remission period, and initial tumor size. "
|3.||Body Weight (Weight, Body)
12/01/2007 - "Disruption of local IGF-I dramatically reduced body weight 28-37%, femur areal bone mineral density 10-25%, and femur bone size 18-24% in growing mice. "
07/01/2008 - "The current treatment using an initial low dose of hrGH followed by individualised dose titration adjusted according to serum IGF-1 levels, leads to similar beneficial effects with less incidence of side effects, improved tolerance to treatment and a lower stable GH dose as compared to hrGH replacement therapy based on body weight or body surface area. "
11/01/2003 - "As compared with healthy rats, administration of 20 microg human recombinant IGF-I/kg body weight for 14 d to cirrhotic rats significantly improved N balance variables and restored in vivo intestinal transport of the sugar. "
02/01/2003 - "In IGF-I-treated rats, serum concentration of IGF-I and final body weight were significantly greater because of a proportionate increase in carcass lean body mass than in vehicle-treated rats. "
01/01/1995 - "The reduction of GH secretion was associated with a decreased body weight and a significant reduction in plasma IGF-I concentration. "
04/01/2005 - "This study shows that cardiac indices, insulin resistance and body composition were not different between patients with complete biochemical remission and those with discordant GH and IGF-I levels. "
05/01/2005 - "In non-GHD subjects, 12 months of GH treatment withdrawal significantly decreased IGF-I levels, IMT (to 0.54 +/- 0.06 mm; P < 0.001 vs. baseline), systolic and diastolic peak velocities, and improved insulin resistance. "
06/01/2008 - "Low-dose GH replacement in women with GHD decreased total and visceral adipose tissue and improved cardiovascular markers, with a relatively modest increase in IGF-1 levels and without worsening insulin resistance."
01/01/2004 - "A patient with an IGF1 gene deletion was shown to have severe insulin resistance that improved with IGF-I therapy. "
01/01/1994 - "Metabolic control in patients with extreme insulin resistance is improved after using IGF-1. "
|5.||Wounds and Injuries (Trauma)
11/01/2007 - "Incremental elevation in GH and IGF-1 were associated with significantly improved wound edge epithelialization and cell-layer thickness at high doses (p < 0.005). "
05/15/2007 - "In steroid-treated rats, both IGF-I gel and IGF-I dressing enhanced excisional healing, as shown by a significant reduction in wound size (P = 0.0001), with IGF-I released from the dressing being even more effective than IGF-I gel (P = 0.03). "
05/01/2005 - "In the healthy sheep there was a statistically significant (p < 0.05) improvement in reepithelialization in IGF-1 packed wounds at day 28 (89% for IGF-1 versus 44% for controls). "
09/01/2007 - "Moreover, improved healing of diabetic wounds by addition of recombinant IGF-1 protein was associated with an increase in Hif-1alpha protein synthesis and function in vivo."
05/01/2011 - "The purpose of this study was to determine whether or not a single application of platelet-rich plasma (PRP) in a ruptured tendon alters the expression of IGF-I in the early phase of healing in an animal wound model. "
|1.||Insulin-Like Growth Factor I (IGF-1)
|3.||Growth Hormone (Somatotropin)
|4.||Insulin-Like Growth Factor Binding Protein 3
|6.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||Insulin-Like Growth Factor II (Somatomedin A)
|9.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|5.||Transplantation (Transplant Recipients)